Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2007

View Archived Issues

New data on oblimersen pharmacokinetics, in vivo activity reported

New agents for treating neurological disorders disclosed in recent patents

Pharmacokinetics, pharmacodynamics of fospropofol studied

CNTNAP2 may be a candidate gene for autism

Nereus Pharmaceuticals' NPI-0052, NPI-2358 assessed in phase I cancer studies

Oxaliplatin formulation MBP-426 well tolerated in phase I study

Celtic Pharma completes enrollment in phase IIb TA-NIC study

Coley and Pfizer nominate second TLR9 agonist for clinical development

N30 Pharma enters S-nitrosothiol license agreement with NitroMed

Ipsen and Debiopharm extend their commercialization agreement for Decapeptyl

Gene Logic changes name to Ore Pharmaceuticals and sells genomics assets

Organon enters license agreement with Endotis for antithrombotic compounds

Apthera completes end of phase II meeting with FDA for NeuVax for breast cancer

Novo Nordisk licenses ghrelin antagonist program to Sapphire for treatment of obesity

ArQule initiates two phase II trials of ARQ-197

MAP initiates phase IIa clinical trial of MAP-0005 for asthma

Merck Serono signs agreement with the Ecole Polytechnique Federale de Lausanne

Nycomed signs partnership agreement with NPS to develop and commercialize Gattex

MedImmune and Seattle Genetics further their antibody-drug conjugate collaboration

Collegium successfully completes proof-of-concept study for oral oxycodone COL-003

FibroGen reports novel HIF prolyl hydroxylase inhibitors in a recent patent

Recent patents describe new treatment options for diabetes and associated disorders

Toll-like receptor 3 may be involved in the pathogenesis of Alzheimer's disease

GSK launches Atriance for treatment of lymph cancer

Novartis launches Exelon transdermal patch for treatment of Alzheimer's dementia

Bayer temporarily suspends worldwide marketing of Trasylol

Selective muscarinic agonists with potential for neurological disorders presented at SfN

Choline derivative a potential candidate for neurodegenerative and cognition disorders

Selective nAChR allosteric modulator safe and effective in improving cognition in rodents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....